Importer of Controlled Substances; Notice of Application, 60693-60695 [E7-21009]
Download as PDF
<![CDATA[
60693
mstockstill on PROD1PC66 with NOTICES
Federal Register / Vol. 72, No. 206 / Thursday, October 25, 2007 / Notices
bonding on July 13, 2007 and July 20,
2007.
Having examined the record in this
investigation, including the submissions
on review and responses thereto, the
Commission has determined that there
is a violation of section 337 with respect
to claim 7 of the ‘957 patent; claims 18,
81, 93, 149, and 164 of the ‘439 patent,
claims 83 and 84 of the ‘377 patent;
claims 19 and 20 of the ‘148 patent;
claim 1 of the ‘401 patent; claims 1, 2,
3, and 9 of the ‘917 patent; claims 1, 31,
and 34 of the ‘902 patent; claims 1, 10,
and 14 of the ‘422 patent; claim 1 of the
‘053 patent; and claim 21 of the ‘397
patent.
The Commission has also made
determinations on the issues of remedy,
the public interest, and bonding, as well
as relief against defaulting respondents.
The Commission determined that the
appropriate form of relief in this
investigation is a general exclusion
order, limited exclusion order, and
cease and desist orders.
The general exclusion order prohibits
the unlicensed entry of ink cartridges
for consumption covered by one or more
of claim 7 the ‘957 patent; claims 18, 81,
93, 149, and 164 of the ‘439 patent;
claims 83 and 84 of the ‘377 patent;
claims 19 and 20 of the ‘148 patent;
claim 1 of the ‘401 patent; claims 1, 2,
3, and 9 of the ‘917 patent; claims 1, 31,
and 34 of the ‘902 patent; claims 1, 10,
and 14 of the ‘422 patent; claim 1 of the
‘053 patent; and claim 21 of the ‘397
patent.
The limited exclusion order prohibits
the unlicensed entry for consumption of
certain ink cartridges that are covered
by one or more of claim 165 of the ‘439
patent and claims 29, 31, 34, and 38 of
the ‘472 patent that are manufactured
abroad by or on behalf of, or imported
by or on behalf of defaulting
respondents Glory South Software Mfg.,
Butterfly Image Corp., Mipo
International (‘‘Mipo’’), Mipo America
Ltd. (‘‘Mipo America’’), AcuJet USA,
Tully Imaging Supplies, Ltd. (‘‘Tully’’),
Wellink Trading Co., Ltd. (‘‘Wellink’’),
and Ribbon Tree (Macao) Trading Co.
(‘‘Ribbon Tree Macao’’) or any of their
affiliated companies, parents,
subsidiaries, or other related business
entities, or their successors or assigns.
The limited exclusion order also
prohibits the unlicensed entry for
consumption of certain ink cartridges
that are covered by one or more of
claims 45, 53, and 54 of the ‘397 patent
that are manufactured abroad by or on
behalf of, or imported by or on behalf
of Mipo, Mipo America, Tully, Wellink,
and Ribbon Tree Macao or any of their
affiliated companies, parents,
VerDate Aug<31>2005
17:26 Oct 24, 2007
Jkt 214001
subsidiaries, or other related business
entities, or their successors or assigns.
The Commission has also determined
to issue cease and desist orders covering
claim 7 of the ‘957 patent; claims 18, 81,
93, 149, and 164 of the ‘439 patent;
claims 83 and 84 of the ‘377 patent;
claims 19 and 20 of the ‘148 patent;
claim 1 of the ‘401 patent; claims 1, 2,
3 and 9 of the ‘917 patent; claims 1, 31
and 34 of the ‘902 patent; claims 1, 10
and 14 of the ‘422 patent; claim 1 of the
‘053 patent; and claim 21 of the ‘397
patent and directed to domestic
respondents Ninestar U.S., Town Sky,
Dataproducts, and MMC.
The Commission has further
determined to issue cease and desist
orders covering claim 7 of the ‘957
patent; claims 18, 81, 93, 149, 164, and
165 of the ‘439 patent; claims 83 and 84
of the ‘377 patent; claims 19 and 20 of
the ‘148 patent; claims 29, 31, 34, and
38 of the ‘472 patent; claim 1 of the ‘401
patent; claims 1, 2, 3 and 9 of the ‘917
patent; claims 1, 31 and 34 of the ‘902
patent; claims 1, 10 and 14 of the ‘422
patent; claim 1 of the ‘053 patent; and
claims 21, 45, 53, and 54 of the ‘397
patent (Mipo America only) and
directed to defaulting domestic
respondents Glory South
Manufacturing, Mipo America, and
AcuJet U.S.A.
The Commission has determined that
the public interest factors enumerated in
19 U.S.C. § 1337(d), (f), and (g) do not
preclude issuance of the aforementioned
remedial orders, and that the bond
during the Presidential period of review
shall be set at $13.60 per cartridge for
covered ink cartridges.
The authority for the Commission’s
determinations is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in
sections 210.45–210.51 of the
Commission’s Rules of Practice and
Procedure (19 CFR 210.45–210.51).
By order of the Commission.
Issued: October 19, 2007.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E7–20983 Filed 10–24–07; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
substance in schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such substances, provide manufacturers
holding registrations for the bulk
manufacture of the substance an
opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on April
13, 2007, Research Triangle Institute,
Kenneth H. Davis Jr., Hermann Building
East Institute Drive, P.O. Box 12194,
Research Triangle Park, North Carolina
27709, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as an importer of
the basic classes of controlled
substances listed in schedule I and II:
Drug
1-(1-Phenylcyclohexyl)pyrrolidine
(7458).
1-[1-(2Thienyl)cyclohexy]piperidine
(7470).
1-[1-(2Thienyl)cyclohexyl]pyrrolidine
(7473).
1-Methyl-4-phenyl-4propionoxypiperidine (9661).
1-(2-Phenylethyl)-4-phenyl-4acetoxypiperidine (9663).
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7348).
2,5-Dimethoxy-4ethylamphetamine (7399).
2,5-Dimethoxyamphetamine
(7396).
3,4,5-Trimethoxyamphetamine
(7390).
3,4-Methylenedioxyamphetamine
(7400).
3,4Methylenedioxymethamphetamine (7405).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3-Methylfentanyl (9813) ................
3-Methylthiofentanyl (9833) ..........
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
4-Methylaminorex (cis isomer)
(1590).
4-Methoxyamphetamine (7411) ...
5-Methoxy-3,4methylenedioxyamphetamine
(7401).
5-Methoxy-N,Ndiisopropyltryptamine (7439).
Acetorphine (9319) .......................
Acetyl-alpha-methylfentanyl
(9815).
Acetyldihydrocodeine (9051) ........
Acetylmethadol (9601) .................
Allylprodine (9602) .......................
Alphacetylmethadol except levoalphacetylmethadol (9603).
E:\FR\FM\25OCN1.SGM
25OCN1
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
60694
Federal Register / Vol. 72, No. 206 / Thursday, October 25, 2007 / Notices
mstockstill on PROD1PC66 with NOTICES
Drug
Schedule
Alpha-ethyltryptamine (7249) .......
Alphameprodine (9604) ................
Alphamethadol (9605) ..................
Alpha-methylfentanyl (9814) ........
Alpha-methylthiofentanyl (9832) ...
Alpha-methyltryptamine (7432) ....
Aminorex (1585) ...........................
Benzethidine (9606) .....................
Benzylmorphine (9052) ................
Betacetylmethadol (9607) ............
Beta-hydroxy-3-methylfentanyl
(9831).
Beta-hydroxyfentanyl (9830) ........
Betameprodine (9608) ..................
Betamethadol (9609) ....................
Betaprodine (9611) .......................
Bufotenine (7433) .........................
Cathinone (1235) ..........................
Clonitazene (9612) .......................
Codeine methylbromide (9070) ....
Codeine-N-Oxide (9053) ..............
Cyprenorphine (9054) ..................
Desomorphine (9055) ...................
Dextromoramide (9613) ...............
Diampromide (9615) .....................
Diethylthiambutene (9616) ...........
Diethyltryptamine (7434) ..............
Difenoxin (9168) ...........................
Dihydromorphine (9145) ...............
Dimenoxadol (9617) .....................
Dimepheptanol (9618) ..................
Dimethylthiambutene (9619) ........
Dimethyltryptamine (7435) ...........
Dioxaphetyl butyrate (9621) .........
Dipipanone (9622) ........................
Drotebanol (9335) ........................
Ethylmethylthiambutene (9623) ....
Etonitazene (9624) .......................
Etorphine except HCl (9056) ........
Etoxeridine (9625) ........................
Fenethylline (1503) .......................
Furethidine (9626) ........................
Gamma
Hydroxybutyric
Acid
(2010).
Heroin (9200) ...............................
Hydromorphinol (9301) .................
Hydroxypethidine (9627) ..............
Ibogaine (7260) ............................
Ketobemidone (9628) ...................
Levomoramide (9629) ..................
Levophenacylmorphan (9631) ......
Lysergic acid diethylamide (7315)
Marihuana (7360) .........................
Mecloqualone (2572) ....................
Mescaline (7381) ..........................
Methaqualone (2565) ...................
Methcathinone (1237) ..................
Methyldesorphine (9302) ..............
Methyldihydromorphine (9304) .....
Morpheridine (9632) .....................
Morphine methylbromide (9305) ..
Morphine methylsulfonate (9306)
Morphine-N-Oxide (9307) .............
Myrophine (9308) .........................
N,N-Dimethylamphetamine (1480)
N-[1-(2-thienyl)methyl-4-piperidyl]N-phenylpropanamide (9834).
N-[1-benzyl-4-piperidyl]-Nphenylpropanamide (9818).
N-Benzylpiperazine (7493) ...........
N-Ethyl-3-piperidyl
benzilate
(7482).
N-Ethylamphetamine (1475) ........
N-Ethyl-l-phencylcyclohexylamine
(7455).
VerDate Aug<31>2005
17:26 Oct 24, 2007
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Jkt 214001
Drug
Schedule
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
Nicocodeine (9309) ......................
Nicomorphine (9312) ....................
N-Methyl-3-piperidyl
benzilate
(7484).
Noracymethadol (9633) ................
Norlevorphanol (9634) ..................
Normethadone (9635) ..................
Normorphine (9313) .....................
Norpipanone (9636) .....................
Para-Fluorofentanyl (9812) ..........
Parahexyl (7374) ..........................
Peyote (7415) ...............................
Phenadoxone (9637) ....................
Phenampromide (9638) ................
Phenomorphan (9647) .................
Phenoperidine (9641) ...................
Pholcodine (9314) ........................
Piritramide (9642) .........................
Proheptazine (9643) .....................
Properidine (9644) ........................
Propiram (9649) ...........................
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Racemoramide (9645) ..................
Tetrahydrocannabinols (7370) .....
Thebacon (9315) ..........................
Thiofentanyl (9835) ......................
Thiophene
analog
of
phencyclidine (7470).
Tilidine (9750) ...............................
Trimeperidine (9646) ....................
1-Phenylcyclohexylamine (7460)
1Piperidinocyclohexanecarbonitrile (8603).
Alfentanil (9737) ...........................
Alphaprodine (9010) .....................
Amobarbital (2125) .......................
Amphetamine (1100) ....................
Anileridine (9020) .........................
Bezitramide (9800) .......................
Carfentanil (9743) .........................
Codeine (9050) .............................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Dihydrocodeine (9120) .................
Dihydroetorphine (9334) ...............
Diphenoxylate (9170) ...................
Ethylmorphine (9190) ...................
Etorphine Hcl (9059) ....................
Fentanyl (9801) ............................
Glutethimide (2550) ......................
Hydrocodone (9193) .....................
Hydromorphone (9150) ................
Isomethadone (9226) ...................
Levo-alphacetylmethadol (9648) ..
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Lisdexamfetamine (1205) .............
Meperidine (9230) ........................
Meperidine intermediate-A (9232)
Meperidine intermediate-B (9233)
Meperidine intermediate-C (9234)
Metazocine (9240) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Metopon (9260) ............................
Moramide intermediate (9802) .....
Morphine (9300) ...........................
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Drug
Nabilone (7379) ............................
Opium, raw (9600) .......................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture(9630) ....................
Opium, granulated (9640) ............
Oxycodone (9143) ........................
Oxymorphone (9652) ...................
Pentobarbital (2270) .....................
Phenazocine (9715) .....................
Phencyclidine (7471) ....................
Phenmetrazine (1631) ..................
Phenylacetone (8501) ..................
Piminodine (9730) ........................
Powdered opium (9639) ...............
Racemethorphan (9732) ..............
Racemorphan (9733) ...................
Remifentanil (9739) ......................
Secobarbital (2315) ......................
Sufentanil (9740) ..........................
Thebaine (9333) ...........................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import small
quantities of the listed controlled
substances for the National Institute of
Drug Abuse (NIDA) for research
activities.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537; or any being sent via express
mail should be sent to, Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 2401 JeffersonDavis Highway, Alexandria, Virginia
22301; and must be filed no later than
November 26, 2007.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in Schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
E:\FR\FM\25OCN1.SGM
25OCN1
Federal Register / Vol. 72, No. 206 / Thursday, October 25, 2007 / Notices
Dated: October 19, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–21009 Filed 10–24–07; 8:45 am]
Dated: October 16, 2007.
Michael C. Collins,
Executive Director.
[FR Doc. E7–21034 Filed 10–24–07; 8:45 am]
BILLING CODE 6820–MA–P
NATIONAL COUNCIL ON DISABILITY
NATIONAL COUNCIL ON DISABILITY
Youth Advisory Committee Meetings
(Teleconferences)
Cultural Diversity Advisory Committee
Meeting (Teleconference)
AGENCY:
National Council on Disability
(NCD). Pursuant to the Federal Advisory
Committee Act, Public Law 92–463,
NCD gives notice that the Cultural
Diversity Advisory Committee will hold
a meeting on the date and time noted
below. The Committee will meet by
conference call.
Date and Time: Thursday, November
15, 2007, 2 p.m. Eastern Standard Time.
Place: National Council on Disability,
1331 F Street, NW., Suite 850,
Washington, DC 20004.
Status: All parts of this conference
call will be open to the public. People
interested in participating on this call
should contact the appropriate staff
member listed below. Due to limited
resources, only a few telephone lines
will be available for the conference call.
Agenda: Roll call, announcements,
reports, new business, adjournment. A
detailed agenda will be posted 10 days
before each meeting at https://
www.ncd.gov/newsroom/advisory/
cultural/cultural.htm.
Contact Person for More Information:
To obtain information on the meeting,
including the call-in number, please
contact Mark Seifarth or Stacey Brown,
NCD, 1331 F Street NW., Suite 850,
Washington, DC 20004, 202–272–2004
(voice), 202–272–2074 (TTY), 202–272–
2022 (fax), cultural-diversity@ncd.gov
(e-mail).
Cultural Diversity Advisory
Committee Mission: The purpose of
NCD’s Cultural Diversity Advisory
Committee is to provide advice and
recommendations to NCD on issues
affecting people with disabilities from
culturally diverse backgrounds.
Specifically, the committee will help
identify issues, expand outreach, infuse
participation, and elevate the voices of
underserved and unserved segments of
this nation’s population that will help
NCD develop federal policy that will
address the needs and advance the civil
and human rights of people from
diverse cultures.
Accommodations: People needing
reasonable accommodations should
notify NCD at least two weeks before
these meetings.
mstockstill on PROD1PC66 with NOTICES
VerDate Aug<31>2005
17:26 Oct 24, 2007
Jkt 214001
NUCLEAR REGULATORY
COMMISSION
Final Regulatory Guides: Issuance,
Availability
Nuclear Regulatory
Commission.
ACTION: Issuance, Availability of
Regulatory Guides 1.84, 1.147, and
1.193.
AGENCY:
BILLING CODE 4410–09–P
AGENCY:
60695
National Council on Disability
(NCD).
Pursuant to the Federal Advisory
Committee Act, P. L. 92–463, NCD gives
notice that the Youth Advisory
Committee will hold meetings on the
dates and times noted below. The
Committee will meet by conference call.
All meetings are open to the public.
DATES AND TIMES:
Thursday, November 15, 2007, 4 p.m.
EST.
Thursday, January 17, 2008, 4 p.m.
EST.
Thursday, April 17, 2008, 4 p.m. EDT.
Place: National Council on Disability,
1331 F Street, NW., Suite 850,
Washington, DC
Status: All parts of these conference
calls will be open to the public. People
interested in observing on conference
calls should contact the appropriate
staff member listed below. Due to
limited resources, only a few telephone
lines will be available for each
conference call.
Agenda: Roll call, announcements,
reports, new business, adjournment. A
detailed agenda will be posted 10 days
before each meeting at https://
www.ncd.gov/newsroom/advisory/
youth/youth.htm.
FOR FURTHER INFORMATION CONTACT:
Gerrie Drake Hawkins, Ph.D., Senior
Program Analyst, National Council on
Disability, 1331 F Street, NW., Suite
850, Washington, DC 20004; 202–272–
2004 (voice), 202–272–2074 (TTY), 202–
272–2022 (fax), youth@ncd.gov (e-mail).
Accommodations: People needing
reasonable accommodations should
notify NCD at least two weeks before
this meeting.
Youth Advisory Committee Mission:
The purpose of NCD’s Youth Advisory
Committee is to provide input into NCD
activities consistent with the values and
goals of the Americans with Disabilities
Act.
Dated: October 16, 2007.
Michael C. Collins,
Executive Director.
[FR Doc. E7–21033 Filed 10–24–07; 8:45 am]
BILLING CODE 6820–MA–P
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Wallace E. Norris, U.S. Nuclear
Regulatory Commission, Washington,
DC 20555–0001, telephone (301) 415–
6796 or e-mail to WEN@nrc.gov.
SUPPLEMENTARY INFORMATION: The U.S.
Nuclear Regulatory Commission (NRC)
has issued revisions to existing guides
in the agency’s ‘‘Regulatory Guide’’
series. This series was developed to
describe and make available to the
public information such as methods that
are acceptable to the NRC staff for
implementing specific parts of the
agency’s regulations, techniques that the
staff uses in evaluating specific
problems or postulated accidents, and
data that the staff needs in its review of
applications for permits and licenses.
Revision 34 of Regulatory Guide 1.84,
‘‘Design, Fabrication, and Materials
Code Case Acceptability, ASME Section
III,’’ lists all Section III Code Cases that
the NRC has approved for use. For
Revision 34 of the guide, the NRC staff
reviewed the Section III Code Cases
listed in Supplements 7–12 to the 2001
Edition of the American Society of
Mechanical Engineers (ASME) Boiler
and Pressure Vessel (BPV) Code and
Supplement 1 to the 2004 Edition.
Appendix A to this guide lists the
supplements reviewed, the applicable
edition, and the date on which each
supplement was approved by the ASME
Board on Nuclear Codes and Standards.
Appendix B is a list of the Section III
Code Cases addressed in the seven
supplements. Finally, Appendix C is a
current list of all Section III Code Cases.
In October 2006, the NRC published
a draft of this guide as Draft Regulatory
Guide (DG)–1133. The public comment
period closed on January 2, 2007. The
staff’s responses to the public comments
are located in the NRC’s Agencywide
Documents Access and Management
System (ADAMS), Accession Number
ML072080205.
For Revision 15 of Regulatory Guide
1.147, ‘‘Inservice Inspection Code Case
Acceptability, ASME Section XI,
Division I,’’ the NRC staff reviewed the
Section XI Code Cases listed in
Supplements 7–12 to the 2001 Edition,
and Supplement 1 to the 2004 Edition
of the ASME BPV Code. Appendix A to
E:\FR\FM\25OCN1.SGM
25OCN1
]]>Agencies
[Federal Register Volume 72, Number 206 (Thursday, October 25, 2007)]
[Notices]
[Pages 60693-60695]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-21009]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this section to a bulk manufacturer of a
controlled substance in schedule I or II and prior to issuing a
registration under 21 U.S.C. 952(a)(2) authorizing the importation of
such substances, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on April 13, 2007, Research Triangle Institute, Kenneth H. Davis
Jr., Hermann Building East Institute Drive, P.O. Box 12194, Research
Triangle Park, North Carolina 27709, made application by renewal to the
Drug Enforcement Administration (DEA) for registration as an importer
of the basic classes of controlled substances listed in schedule I and
II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
1-(1-Phenylcyclohexyl)pyrrolidine (7458)... I
1-[1-(2-Thienyl)cyclohexy]piperidine (7470) I
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine I
(7473).
1-Methyl-4-phenyl-4-propionoxypiperidine I
(9661).
1-(2-Phenylethyl)-4-phenyl-4- I
acetoxypiperidine (9663).
2,5-Dimethoxy-4-(n)- I
propylthiophenethylamine (7348).
2,5-Dimethoxy-4-ethylamphetamine (7399).... I
2,5-Dimethoxyamphetamine (7396)............ I
3,4,5-Trimethoxyamphetamine (7390)......... I
3,4-Methylenedioxyamphetamine (7400)....... I
3,4-Methylenedioxymethamphetamine (7405)... I
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3-Methylfentanyl (9813).................... I
3-Methylthiofentanyl (9833)................ I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
4-Methylaminorex (cis isomer) (1590)....... I
4-Methoxyamphetamine (7411)................ I
5-Methoxy-3,4-methylenedioxyamphetamine I
(7401).
5-Methoxy-N,N-diisopropyltryptamine (7439). I
Acetorphine (9319)......................... I
Acetyl-alpha-methylfentanyl (9815)......... I
Acetyldihydrocodeine (9051)................ I
Acetylmethadol (9601)...................... I
Allylprodine (9602)........................ I
Alphacetylmethadol except levo- I
alphacetylmethadol (9603).
[[Page 60694]]
Alpha-ethyltryptamine (7249)............... I
Alphameprodine (9604)...................... I
Alphamethadol (9605)....................... I
Alpha-methylfentanyl (9814)................ I
Alpha-methylthiofentanyl (9832)............ I
Alpha-methyltryptamine (7432).............. I
Aminorex (1585)............................ I
Benzethidine (9606)........................ I
Benzylmorphine (9052)...................... I
Betacetylmethadol (9607)................... I
Beta-hydroxy-3-methylfentanyl (9831)....... I
Beta-hydroxyfentanyl (9830)................ I
Betameprodine (9608)....................... I
Betamethadol (9609)........................ I
Betaprodine (9611)......................... I
Bufotenine (7433).......................... I
Cathinone (1235)........................... I
Clonitazene (9612)......................... I
Codeine methylbromide (9070)............... I
Codeine-N-Oxide (9053)..................... I
Cyprenorphine (9054)....................... I
Desomorphine (9055)........................ I
Dextromoramide (9613)...................... I
Diampromide (9615)......................... I
Diethylthiambutene (9616).................. I
Diethyltryptamine (7434)................... I
Difenoxin (9168)........................... I
Dihydromorphine (9145)..................... I
Dimenoxadol (9617)......................... I
Dimepheptanol (9618)....................... I
Dimethylthiambutene (9619)................. I
Dimethyltryptamine (7435).................. I
Dioxaphetyl butyrate (9621)................ I
Dipipanone (9622).......................... I
Drotebanol (9335).......................... I
Ethylmethylthiambutene (9623).............. I
Etonitazene (9624)......................... I
Etorphine except HCl (9056)................ I
Etoxeridine (9625)......................... I
Fenethylline (1503)........................ I
Furethidine (9626)......................... I
Gamma Hydroxybutyric Acid (2010)........... I
Heroin (9200).............................. I
Hydromorphinol (9301)...................... I
Hydroxypethidine (9627).................... I
Ibogaine (7260)............................ I
Ketobemidone (9628)........................ I
Levomoramide (9629)........................ I
Levophenacylmorphan (9631)................. I
Lysergic acid diethylamide (7315).......... I
Marihuana (7360)........................... I
Mecloqualone (2572)........................ I
Mescaline (7381)........................... I
Methaqualone (2565)........................ I
Methcathinone (1237)....................... I
Methyldesorphine (9302).................... I
Methyldihydromorphine (9304)............... I
Morpheridine (9632)........................ I
Morphine methylbromide (9305).............. I
Morphine methylsulfonate (9306)............ I
Morphine-N-Oxide (9307).................... I
Myrophine (9308)........................... I
N,N-Dimethylamphetamine (1480)............. I
N-[1-(2-thienyl)methyl-4-piperidyl]-N- I
phenylpropanamide (9834).
N-[1-benzyl-4-piperidyl]-N- I
phenylpropanamide (9818).
N-Benzylpiperazine (7493).................. I
N-Ethyl-3-piperidyl benzilate (7482)....... I
N-Ethylamphetamine (1475).................. I
N-Ethyl-l-phencylcyclohexylamine (7455).... I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
Nicocodeine (9309)......................... I
Nicomorphine (9312)........................ I
N-Methyl-3-piperidyl benzilate (7484)...... I
Noracymethadol (9633)...................... I
Norlevorphanol (9634)...................... I
Normethadone (9635)........................ I
Normorphine (9313)......................... I
Norpipanone (9636)......................... I
Para-Fluorofentanyl (9812)................. I
Parahexyl (7374)........................... I
Peyote (7415).............................. I
Phenadoxone (9637)......................... I
Phenampromide (9638)....................... I
Phenomorphan (9647)........................ I
Phenoperidine (9641)....................... I
Pholcodine (9314).......................... I
Piritramide (9642)......................... I
Proheptazine (9643)........................ I
Properidine (9644)......................... I
Propiram (9649)............................ I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
Racemoramide (9645)........................ I
Tetrahydrocannabinols (7370)............... I
Thebacon (9315)............................ I
Thiofentanyl (9835)........................ I
Thiophene analog of phencyclidine (7470)... I
Tilidine (9750)............................ I
Trimeperidine (9646)....................... I
1-Phenylcyclohexylamine (7460)............. II
1-Piperidinocyclohexanecarbonitrile (8603). II
Alfentanil (9737).......................... II
Alphaprodine (9010)........................ II
Amobarbital (2125)......................... II
Amphetamine (1100)......................... II
Anileridine (9020)......................... II
Bezitramide (9800)......................... II
Carfentanil (9743)......................... II
Codeine (9050)............................. II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Dihydrocodeine (9120)...................... II
Dihydroetorphine (9334).................... II
Diphenoxylate (9170)....................... II
Ethylmorphine (9190)....................... II
Etorphine Hcl (9059)....................... II
Fentanyl (9801)............................ II
Glutethimide (2550)........................ II
Hydrocodone (9193)......................... II
Hydromorphone (9150)....................... II
Isomethadone (9226)........................ II
Levo-alphacetylmethadol (9648)............. II
Levomethorphan (9210)...................... II
Levorphanol (9220)......................... II
Lisdexamfetamine (1205).................... II
Meperidine (9230).......................... II
Meperidine intermediate-A (9232)........... II
Meperidine intermediate-B (9233)........... II
Meperidine intermediate-C (9234)........... II
Metazocine (9240).......................... II
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Metopon (9260)............................. II
Moramide intermediate (9802)............... II
Morphine (9300)............................ II
Nabilone (7379)............................ II
Opium, raw (9600).......................... II
Opium extracts (9610)...................... II
Opium fluid extract (9620)................. II
Opium tincture(9630)....................... II
Opium, granulated (9640)................... II
Oxycodone (9143)........................... II
Oxymorphone (9652)......................... II
Pentobarbital (2270)....................... II
Phenazocine (9715)......................... II
Phencyclidine (7471)....................... II
Phenmetrazine (1631)....................... II
Phenylacetone (8501)....................... II
Piminodine (9730).......................... II
Powdered opium (9639)...................... II
Racemethorphan (9732)...................... II
Racemorphan (9733)......................... II
Remifentanil (9739)........................ II
Secobarbital (2315)........................ II
Sufentanil (9740).......................... II
Thebaine (9333)............................ II
------------------------------------------------------------------------
The company plans to import small quantities of the listed
controlled substances for the National Institute of Drug Abuse (NIDA)
for research activities.
Any manufacturer who is presently, or is applying to be, registered
with DEA to manufacture such basic classes of controlled substances may
file comments or objections to the issuance of the proposed
registration and may, at the same time, file a written request for a
hearing on such application pursuant to 21 CFR 1301.43 and in such form
as prescribed by 21 CFR 1316.47.
Any such comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
Washington, DC 20537; or any being sent via express mail should be sent
to, Drug Enforcement Administration, Office of Diversion Control,
Federal Register Representative (ODL), 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be filed no later than November
26, 2007.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e), and (f). As noted in a previous notice published in the Federal
Register on September 23, 1975, (40 FR 43745-46), all applicants for
registration to import a basic class of any controlled substances in
Schedule I or II are and will continue to be required to demonstrate to
the Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration, that the requirements for such registration
pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b),
(c), (d), (e), and (f) are satisfied.
[[Page 60695]]
Dated: October 19, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-21009 Filed 10-24-07; 8:45 am]
BILLING CODE 4410-09-P
